arrow
M

Minming Li

温州医科大学
H指数:32
被引数:4,015

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Recombinant human erythropoietin plus all-trans retinoic acid and testosterone undecanoate for the treatment of anemia in patients with lower-risk myelodysplastic syndromes: a multicenter, single-arm, prospective trial

重组人促红细胞生成素联合全反式维甲酸和十一酸睾酮治疗低危骨髓增生异常综合征患者贫血:一项多中心、单臂、前瞻性试验

2026-02-012
OA
Comparing the efficacy and safety of the ABC-14 regimen (azacitidine, venetoclax, and chidamide) with traditional 3+7 intensive induction regimen or AB-14 regimen (venetoclax combined with azacitidine) in newly diagnosed AML: study protocol for a prospective, multicenter, randomized, open-label clinical trial

比较ABC-14方案(azacitidine、venetoclax和chidamide)与传统3+7强化诱导方案或AB-14方案(venetoclax联合azacitidine)在初诊AML中的疗效和安全性:一项前瞻性、多中心、随机、开放标签临床研究的方案

2025-12-100
PRE
RF008 RECOMBINANT HUMAN ERYTHROPOIETIN PLUS ALL-TRANS RETINOIC ACID AND TESTOSTERONE UNDECANOATE FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES

RF008 重组人红细胞生成素联合全反式维甲酸和十一酸睾酮治疗低危骨髓增生异常综合征患者的贫血

2025-09-010
PRE
Azacitidine, Venetoclax Combined with Chidamide (ABC-14 Regimen) As an Induction Therapy for Newly Diagnosed AML: A Real-World Retrospective Analysis By the ABC-14 Collaboration Group

阿扎胞苷、维奈克拉联合氯米芬(ABC-14方案)作为新诊断AML的诱导治疗:一项由ABC-14协作组进行的真实世界回顾性分析

BLOOD
IF23.1
2024-11-050
PRE
Prognostic Significance of Grade Discrepancy Between Primary Tumor and Venous Thrombus in Nonmetastatic Clear-cell Renal Cell Carcinoma: Analysis of the REMEMBER Registry and Implications for Adjuvant Therapy
2024-02-0111
OA